ATEZOLIZUMAB
atezolizumab 1.2 g/20 mL injection, 20 mL vial
ATEZOLIZUMAB (11926Q)
11926Q
Manner of administration:Injection
Restriction 18257
Indication: Extensive-stage small cell lung cancer
Treatment phase: Initial treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 1200 mg | # of repeats: 3 | DPMA: $6,838.60 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Tecentriq
(atezolizumab 1.2 g/20 mL injection, 20 mL vial)
|
||||
